R
Ryan Spangler
Researcher at Oregon Health & Science University
Publications - 10
Citations - 1380
Ryan Spangler is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Drug repositioning & Insulin receptor. The author has an hindex of 6, co-authored 9 publications receiving 278 citations. Previous affiliations of Ryan Spangler include Broad Institute & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Copper induces cell death by targeting lipoylated TCA cycle proteins
Peter Tsvetkov,Shannon Coy,Boryana Petrova,Margaret Dreishpoon,A. Verma,Mai Abdusamad,Jordan Rossen,Lena M. Joesch-Cohen,Ranad Humeidi,Ryan Spangler,John K. Eaton,Evgeni M. Frenkel,Mustafa Koçak,Steven M. Corsello,Svetlana Lutsenko,Naama Kanarek,Sandro Santagata,Todd R. Golub +17 more
TL;DR: It is shown in human cells that copper-dependent, regulated cell death is distinct from known death mechanisms and is dependent on mitochondrial respiration, and that excess copper promotes the aggregation of lipoylated proteins and links mitochondrial metabolism to copper- dependent death.
Journal ArticleDOI
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Steven M. Corsello,Steven M. Corsello,Rohith T. Nagari,Ryan Spangler,Jordan Rossen,Mustafa Kocak,Jordan Bryan,Jordan Bryan,Ranad Humeidi,David Peck,Xiaoyun Wu,Anna Tang,Vickie M. Wang,Sam Bender,Evan Lemire,Rajiv Narayan,Philip Montgomery,Uri Ben-David,Uri Ben-David,Colin W. Garvie,Yii-Der Ida Chen,Matthew G. Rees,Nicholas J. Lyons,James M. McFarland,Bang Wong,Li Wang,Nancy Dumont,Patrick O'Hearn,Eric Stefan,Eric Stefan,John G. Doench,Caitlin N. Harrington,Heidi Greulich,Matthew Meyerson,Matthew Meyerson,Francisca Vazquez,Ayshwarya Subramanian,Jennifer Roth,Joshua Bittker,Joshua Bittker,Jesse S. Boehm,Christopher C. Mader,Aviad Tsherniak,Todd R. Golub +43 more
TL;DR: An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines in a manner predictable from the cell lines' molecular features.
Journal ArticleDOI
Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging.
Dimitrios Kapogiannis,Maja Mustapić,Michelle Shardell,Sean T. Berkowitz,Thomas C. Diehl,Ryan Spangler,Joyce Tran,Michael P. Lazaropoulos,Sahil Chawla,Seema Gulyani,Erez Eitan,Yang An,Chiung-Wei Huang,Esther S. Oh,Constantine G. Lyketsos,Susan M. Resnick,Edward J. Goetzl,Luigi Ferrucci +17 more
TL;DR: NEV biomarker candidates were validated and it was demonstrated that their preclinical longitudinal trajectories can predict AD diagnosis and motivate further development of nEV biomarkers toward a clinical blood test for AD.
Journal ArticleDOI
In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles
Erez Eitan,Valeria Tosti,Caitlin N. Suire,Edda Cava,Sean T. Berkowitz,Beatrice Bertozzi,Sophia M. Raefsky,Nicola Veronese,Nicola Veronese,Ryan Spangler,Francesco Spelta,Francesco Spelta,Maja Mustapić,Dimitrios Kapogiannis,Mark P. Mattson,Mark P. Mattson,Luigi Fontana,Luigi Fontana +17 more
TL;DR: Increased levels of leptin receptor in the PR group in total plasma EVs and in a subpopulation of plasma EVs expressing the neuronal marker L1CAM are found, consistent with improved insulin and leptin sensitivity in response to PR and open a new window for following physiologic responses to dietary interventions in humans.
Posted ContentDOI
Non-oncology drugs are a source of previously unappreciated anti-cancer activity
Steven M. Corsello,Steven M. Corsello,Rohith T. Nagari,Ryan Spangler,Jordan Rossen,Mustafa Kocak,Jordan Bryan,Ranad Humeidi,David Peck,Xiaoyun Wu,Anna Tang,Vickie M. Wang,Sam Bender,Evan Lemire,Rajiv Narayan,Philip Montgomery,Uri Ben-David,Yii-Der Ida Chen,Matthew G. Rees,Nicholas J. Lyons,James M. McFarland,Bang Wong,Li Wang,Nancy Dumont,Patrick O'Hearn,Eric Stefan,John G. Doench,Heidi Greulich,Matthew Meyerson,Matthew Meyerson,Francisca Vazquez,Ayshwarya Subramanian,Jennifer Roth,Joshua Bittker,Jesse S. Boehm,Christopher C. Mader,Aviad Tsherniak,Todd R. Golub +37 more
TL;DR: The results illustrate the potential of the PRISM drug repurposing resource as a starting point for new oncology therapeutic development and relative barcode abundance following treatment thus reflects cell line viability.